RGDFAP: platelet aggregation inhibitory and profibrinolytic hybrid peptide (RGDF coupled with the carboxy terminal part of alpha 2-antiplasmin) enhances plasminogen binding to platelets.

Udvardy, M; Schwartzott, D; Jackson, K; Posan, E; Rak, K; McKee, P A

Udvardy, M; Schwartzott, D; Jackson, K; Posan, E; Rak, K; McKee, P A.

Affiliation

Udvardy M; 2nd Department of Medicine, Debrecen University Medical School, Hungary.

Blood Coagul Fibrinolysis ; 6(5): 481-5, 1995 Jul.

Article in En | MEDLINE | ID: mdl-8589217

Subject(s)

Blood Platelets/drug effects; Blood Platelets/metabolism; Fibrinolysis/drug effects; Peptides/pharmacology; Plasminogen/metabolism; Platelet Aggregation Inhibitors/pharmacology; Platelet Aggregation/drug effects; Amino Acid Sequence; Flow Cytometry; Fluorescein-5-isothiocyanate; Humans; Molecular Sequence Data; Oligopeptides/chemistry; Protein Multimerization; alpha-2-Antiplasmin/chemistry

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Peptides / Plasminogen / Blood Platelets / Platelet Aggregation Inhibitors / Platelet Aggregation / Fibrinolysis Limits: Humans Language: En Journal: Blood Coagul Fibrinolysis Journal subject: ANGIOLOGIA / HEMATOLOGIA Year: 1995 Document type: Article Affiliation country: Hungary Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links